Cue Biopharma (CUE) news
Recent news
Cue Biopharma, Inc.: Jefferies adjusts target price to $66 from $4 to reflect reverse stock split
Jefferies has revised its target price for Cue Biopharma, Inc. (CUE) to $66 from $4, a significant adjustment attributed to the company's recent reverse stock split . This move reflects the firm's updated valuation expectations for the clinical-stage biopharmaceutical company, which is engaged in…
AInvest Wire · 3d agoCue Biopharma, Inc. Q2 collaboration revenue USD 7.877 million
Cue Biopharma, Inc. (Nasdaq: CUE) reported collaboration revenue of $2.7 million for the three months ended June 30, 2024, compared to $1.4 million in the same period in 2023. The increase was primarily attributed to Ono Pharmaceutical Co., Ltd. agreement . For the six months ended June 30, 2024,…
AInvest Wire · Aug 14, 2026Cue Biopharma, Inc. Q2 income from operations USD -87.695 million
Cue Biopharma, Inc. (Nasdaq: CUE) reported loss from operations of USD -87.695 million , according to its most recent financial update. This figure reflects the company’s ongoing investment in research and development, as well as general and administrative expenses. The loss from operations for the…
AInvest Wire · Aug 14, 2026Cue Biopharma announces appointment of James M. Ahlers as chief financial officer and Cue-221 investigational new drug submission
AInvest Wire · Aug 3, 2026Cue Biopharma reports $50M placement
AInvest Wire · Jul 10, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.